Innovent and WeComput Partner For AI-driven Drug Discovery

Innovent Biologics, Inc. (Innovent), a top biopharmaceutical company creating high-quality medications for various diseases, has revealed a collaboration with WeComput to enhance Innovent Biologics’ Artificial Intelligence for Drug Discovery platform. Both parties will work together, leveraging their strengths and technologies to speed up drug discovery and development with the help of AI technology.

Innovent Academy, an essential R&D division of Innovent, has been thoroughly investigating and proactively implementing AI drug research and development. Innovent Academy will use WeComput's WeMol molecular design platform to strengthen its computing structure and speed up drug research and development through collaboration. In the meantime, WeMol will incorporate NVIDIA's BioNeMo to enhance Innovent’s AI systems' computing power and boost computational efficiency.

Innovent and WeMol will join forces to combine their technological expertise in order to build an all-encompassing AI-powered system for drug discovery and development that is efficient, easy to use, digitalized, smart, and automated. This collaboration will enable Innovent to greatly decrease AI implementation and experimental expenses, accelerate the drug R&D process, enhance R&D success rate, and provide patients with more innovative drugs and treatment choices.

Dr. Kaijie He, vice president of oncology biology and ADC Drug Research, said, “AI is injecting new momentum into the global pharmaceutical and biotech industries. We are excited to partner with WeComput and integrate advanced AI technology to boost our R&D capabilities and expedite the discovery and development of innovative drugs. We believe this collaboration will offer robust technical support to our research team, propelling us toward greater breakthroughs in the global pharmaceutical market."